Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411054 | 0.78 | CA12 (0.46) | ALDH1A1 | |
| SCHEMBL8768749 | 0.78 | DGAT1 (0.34) | ALDH1A1 | |
| SCHEMBL28505201 | 0.78 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL8740065 | 0.77 | PEPD (0.37) | ALDH1A1 | |
| SCHEMBL1617977 | 0.77 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL5020785 | 0.77 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL14681167 | 0.77 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL15088191 | 0.74 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL11340495 | 0.70 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL18526347 | 0.70 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119463052-A | Mud-resistant foam-stabilizing slump-retaining material and preparation method thereof | 科之杰新材料集团(广东)有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117551072-A | Preparation method of 3-sulfolane-3-methyl formate | 上海阿拉丁生化科技股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9499531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20150274713-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | CURIA GLOBAL, INC. | 2015-10-01 | — | — | US | disclosed |
| US-5147867-A | Bactericides, (carba)penicillins | MERCK & CO., INC. (US) | 1992-09-15 | — | — | US | disclosed |
| US-5145990-A | Dehydropeptidase, carbapenicillin potentiation | MERCK & CO., INC. (US) | 1992-09-08 | — | — | US | disclosed |
| US-5143908-A | Carboxylic acids containing amino and phosphinyl groups | MERCK & CO., INC. (US) | 1992-09-01 | — | — | US | disclosed |
| US-5099063-A | 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids | MERCK & CO., INC. (US) | 1992-03-24 | — | — | US | disclosed |
| US-4962097-A | IN COMBINATION WITH A CARBAPENEM OR PENEM ANTIBIOTIC | MERCK & CO., INC. (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0366469-A2 | Phosphorus containing enzyme inhibitors | MERCK & CO. INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0266978-A2 | Novel antibacterial agents and potentiators of carbapenem antibiotics | MERCK & CO. INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4715994-A | PHOSPHINIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0210545-A2 | Phosphorous containing enzyme inhibitors | MERCK & CO. INC. (US) | 1987-02-04 | — | — | EP | disclosed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274713-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | ALDH1A1 954/4885L3MBTL1 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.